Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Ipilimumab & Preclinical/Clinical data

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Emerging data from ipilimumab trials suggested that conventional definitions of disease progression and response incompletely reflect overall survival among patients who appear to have a long-term benefit.
Wolchok et al. 2009
Hoos et al. 2010
…

References (Sources)

A prospective phase II trial exploring the association between TME biomarkers & clinical activity of ipilimumab in advanced melanoma
Hamid et al. 2011 Journal of Translational Medicine 9: 204
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Motzer et al., 2013
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi et al., 2010
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients
Santarpia et al., 2013
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Maio et al. 2013
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Ipilimumab & Preclinical/Clinical data

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat